Reducing Chinese API Imports Key For Indian Pharma Growth, Says IPA

IPA Lays Out ‘Vision 2030’ For Indian Pharma Sector

The Indian government has formulated policy to reduce import dependence of APIs from China. The Indian Pharmaceutical Alliance lays out ‘Vision 2030,’ that aims to make the Indian pharma sector, the “world’s largest supplier of drugs by volume.”

India - China
The Indian pharma sector fears that policy shifts by the Chinese government could result in extreme price shifts for certain molecules. • Source: Shutterstock

Indian pharma manufacturers are “at risk of supply disruptions and unexpected price movements” because of their heavy reliance on Chinese exports, a new report by the Indian Pharmaceutical Alliance (IPA) has warned. Outlining the Indian pharma sector’s ‘Vision 2030’, the IPA warned that around 80% by volume of India's requirements for active pharmaceutical ingredients is fulfilled by China. 

Talking exclusively to Generics Bulletin, Sudarshan Jain, secretary general of IPA, said, “The pandemic has revealed the challenges of depending...

More from Manufacturing

More from Business